Mié. Oct 28, 2020

Latino News

Noticias de Hazleton y el mundo

Fundado el 20 de mayo de 2013

Nexus Pharmaceuticals, Inc. Announces Launch of Emerphed™ (ephedrine sulfate) RTU Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#Emerphed–Nexus Pharmaceuticals announced today that it has launched its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial. With no need for compounding, diluting, or mixing, Emerphed saves valuable staff time while also reducing the potential for preparation error and waste.


“We are proud to now have Emerphed available in the market, so that we can supply hospital institutions with the life-saving critical injectables that they have been asking for,” said Mariam S. Darsot, Chief Executive Officer & President of Nexus Pharmaceuticals.

Shahid Ahmed, Chief Scientific Officer added, “By offering a premixed, ready-to-use formulation of ephedrine sulfate, Nexus Pharmaceuticals is seeking to bring safety, stability and simplicity to the operating room.”

Emerphed will be available in a ready-to-use 10 mL vial that does not require further dilution. Each vial contains 50 mg ephedrine sulfate in 0.9% sodium chloride.

About Emerphed

INDICATIONS AND USAGE

Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

WARNINGS AND PRECAUTIONS

Emerphed can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.

CONTRAINDICATIONS

None

OVERDOSAGE

Overdose of Emerphed can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.

To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For full prescribing information, please see the following link.

About Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus Pharmaceuticals ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable, lifesaving treatment options when and where they’re needed most.

Contacts

Diana Lebiecki

847-996-3790

dlebiecki@nexuspharma.net